Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Edoxaban Flounders in US but No Change to FY2017 Biz Targets: Daiichi Sankyo CEO
Daiichi Sankyo will stick to its business targets for the year ending in March 2018 even though its novel oral anticoagulant (NOAC) edoxaban continues to face an uphill battle in the US, President and CEO Joji Nakayama said on November…
To read the full story
Related Article
BUSINESS
- Narcolepsy Diagnosis Still Takes Nearly 9 Years in Japan: Expert
September 28, 2026
- Japan OTC Market Down for 6th Straight Month in August: Intage
September 28, 2026
- IHH Unit Appeals Dismissal of 203 Billion Yen Daiichi Sankyo Suit
September 28, 2026
- J-Pharma Inks Licensing Term Sheet for LAT1 Inhibitor JPH034
September 28, 2026
- Maruho, BMS Forge Japan Marketing Alliance for Sotyktu
September 28, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…